Research Summary

Dr. Steven Seyedin is a radiation oncologist who cares for patients with genitourinary cancers (those of the reproductive and urinary systems). His treatment expertise includes prostate, kidney, bladder and testicular cancer.

His research focuses on integrating advanced technologies, such as stereotactic body radiation therapy (which allows precise delivery of high radiation doses), with other targeted therapies in order to improve patients' chances of beating genitourinary cancers. He enjoys collaborating with other UCSF researchers to usher new treatments from the laboratory to the clinic and offering his patients clinical trials with cutting-edge treatment. His work has been published in JAMA Oncology, Frontiers in Oncology, and the International Journal of Radiation Oncology, Biology, and Physics.

Education

  • B.A.
    University of California, Berkeley, 2008, Biochemistry
  • M.D.
    University of California, Los Angeles, 2014, Medicine
  • Internship
    University of Illinois, Chicago, Illinois, 2016, Medicine
  • Residency
    University of Iowa, Iowa, City, 2020, Medicine

Honors & Awards

  • 2022 
    Association of Residents in Radiation Oncology Educator of the Year
  • 2020
    ASTRO Annual Meeting Resident Recognition Award in Biology
  • 2020
    UIHC Excellence in Clinical Teaching Award 2020
  • 2019
    American Brachytherapy Society HDR LDR Prostate Scholarship Workshop
  • 2019
    RSNA Roentgen Resident Research Award
  • 2019
    ASTRO Annual Meeting Abstract Travel Award
  • 2018
    RSNA Roentgen Resident Research Award,
  • 2012
    David Geffen School of Medicine at UCLA Student Teacher Award

Selected Publications

  1. Harada GK, Seyedin SN, Heutlinger O, Azizi A, Hsu A, Rezazadeh A, Daneshvar M, Gin GE, Uchio EM, Giannico GA, Harris JP, Simon AB, Kuo JV, Mar N. A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy. Adv Radiat Oncol. 2024 Nov 9;10(1):101671. View on PubMed.
  2. Seyedin SN, Harada GK, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, Rezazadeh A, Daneshvar M, Mar N. Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2024 Dec;22(6):102243. View on PubMed.
  3. Heutlinger O, Azizi A, Harada G, Harris JP, Daneshvar M, Gin G, Uchio E, Mar N, Rezazadeh A, Seyedin SN. Socioeconomic Barriers to Receiving Early Salvage Radiotherapy for Locally Advanced Prostate Adenocarcinoma: A Retrospective Single-Center Study. Cureus. 2024 Sep 8;16(9):e68945. View on PubMed.
  4. Seyedin SN, Harada G, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, Daneshvar M, Mar N. Use of Radiation Therapy for Ataxia-Telangiectasia Mutated (ATM)-Mutation Metastatic Renal Cell Carcinoma: A Case Report. Cureus. 2024 Jul 17;16(7):e64781. doi: 10.7759/cureus.64781. View on PubMed.
  5. Yeakel J, Seyedin SN, Harada G, Hagopian G, Mahmood S, Bennett R, Harris JP, Abbott EM, Lindner S, Dayyani F, Sehgal V, Kuo JV, Abi-Jaoudeh N. The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis. Cancers (Basel). 2024 Jun 29;16(13):2401. View on PubMed.
  6. Mar N, Dwabe S, Baranda MN, Zarrabi KK, Eturi A, Gulati S, Parikh M, Seyedin SN, Kalebasty AR. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2024 Apr;22(2):217-223. View on PubMed.
  7. Poellmann MJ, Bu J, Liu S, Wang AZ, Seyedin SN, Chandrasekharan C, Hong H, Kim Y, Caster JM, Hong S. Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients. Biosens Bioelectron. 2023 Apr 15;226:115117. View on PubMed.
  8. Seyedin SN, Bassalow R, Mawlawi OR, Turner LM, Patel RR, Mazin SR, Oderinde OM, Voronenko Y, Wages CA, Olcott PD, Chang JY, Balter PA, Welsh JW. The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study. Front Oncol. 2022 Oct 14;12:921473. View on PubMed.
  9. Dayyani F, Smith BR, Nguyen NT, Daly S, Hinojosa MW, Seyedin SN, Kuo J, Samarasena JB, Lee JG, Taylor TH, Cho MT, Senthil M. A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). Future Oncol. 2022 Jul;18(21):2615-2622. View on PubMed.
  10. Seyedin SN, Watkins JM, Mayo Z, Snow AN, Laszewski M, Russo JK, Mott SL, Tracy CR, Smith MC, Buatti JM, Caster JM. A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy. Adv Radiat Oncol. 2021 Aug 14;6(6):100778. View on PubMed.

View more publications

Go to UCSF Profiles, powered by CTSI